Intranasal ipratropium: literature abstracts and comments

Area of Science:

• Allergy and Immunology
• Pharmacology
• Otorhinolaryngology

Background:

• Perennial rhinitis often presents with severe watery rhinorrhoea, impacting quality of life.
• Existing treatments like glucocorticoids, sodium cromoglycate, and antihistamines may not be effective for all patients.

Purpose of the Study:

• To evaluate the efficacy and tolerability of intranasal ipratropium for managing severe watery rhinorrhoea in perennial rhinitis.

Main Methods:

• A double-blind, placebo-controlled, cross-over trial involving 20 adults with perennial rhinitis.
• Participants received 80 micrograms of intranasal ipratropium four times daily.
• Outcomes measured included reduction in nasal hypersecretion and patient preference.

Main Results:

• Intranasal ipratropium demonstrated a significant reduction in nasal hypersecretion.
• Fourteen out of twenty patients preferred the ipratropium treatment period over placebo.
• The drug was effective even in patients resistant to other rhinitis medications.

Conclusions:

• Intranasal ipratropium is a valuable treatment for severe rhinorrhoea in perennial rhinitis, suitable for both continuous and occasional use.
• Its immediate action allows for use before exposure to known triggers.
• No systemic or local side effects were reported, indicating good tolerability.